Home Subscription Services
 
   

 
The International Journal of Oral & Maxillofacial Implants
OCTE Home Page
About the Editor
Editorial Board
Submit
Author Guidelines
Submission Form
Reprints / Articles
Permissions
Advertising
MEDLINE Search
 
 
 
 
 
FacebookTwitterYouTube
Quintessence Publishing: Journals: OCTE

 

Oral & Craniofacial Tissue Engineering

Edited by Ole T. Jensen, DDS, MS

Official Journal of the Tissue Engineering Society, the Chinese Society of Oral Biomedicine, and the Japanese Society of Regenerative Medicine

ISSN (print) 2158-3722 • ISSN (online) 2158-3706

Publication:
Oral & Craniofacial Tissue Engineering
Summer 2012
Volume 2 , Issue 2

Back
Share Abstract:

A Review of Pharmaceutical Agents and Oral Bone Health: How Osteonecrosis of the Jaw Has Affected the Field

Matthew R. Allen, PhD/Salvatore L. Ruggiero, MD, DMD

Pages: 101–113

Just a decade ago, the outlook appeared limitless for the use of bisphosphonates for the treatment of a large number of metabolic bone diseases ranging from osteoporosis to cancer-related bone alterations to oral bone loss. Soon thereafter, however, osteonecrosis of the jaw (ONJ) emerged as a rare but significant condition associated with bisphosphonate treatment. Although many questions remain concerning ONJ, some significant knowledge has been gained over the past decade. Ideas have emerged regarding how to stage and treat the condition, and a number of preclinical models have been developed that will soon begin to speed progress toward understanding the pathophysiology of this condition. Researchers have also discovered that ONJ is not specific to bisphosphonates, as other potent antiremodeling agents have now been associated with the condition. While antiremodeling agents remain essential tools in medicine, ONJ has somewhat slowed the momentum for this drug class, especially as it relates to new and emerging applications. Until more effective prevention or treatment regimens for ONJ are developed, this side effect of remodeling suppression will continue—for better or worse—to have a significant impact on the field. One potential treatment option may be in the form of osteoanabolics. Exciting new data have emerged demonstrating the efficacy of teriparatide (parathyroid hormone) in reversing oral cavity bone loss and even as a potential therapy for ONJ. ORAL CRANIOFAC TISSUE ENG 2012;2:101–113

Key words: anabolic agents, antiremodeling agents, bisphosphonates, bone remodeling, osteonecrosis of the jaw

Full Text PDF File | Order Article

 

 
Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.
  © 2014 Quintessence Publishing Co Inc
 

Home | Subscription Services | Books | Journals | Multimedia | Events | Blog
Terms of Use | Privacy Policy | About Us | Contact Us | Advertising | Help | Sitemap | Catalog